Core Viewpoint - The performance of equity funds has rebounded significantly, with 54 funds achieving over 100% returns in the past year, highlighting the strong capabilities of fund managers in the current market environment [1]. Group 1: Fund Performance - As of July 25, 2023, 54 funds have recorded returns exceeding 100%, with 34 of these being actively managed funds [1]. - Among the top-performing funds, GF Fund has six products that doubled their returns, leading the industry [1]. - Specific funds from GF Fund include GF Growth Navigation One-Year Holding A, GF Beijing Stock Exchange Selected Two-Year Open A, and GF Growth Start One-Year A, with returns of 131.81%, 118.13%, and 100.65% respectively [1]. Group 2: Investment Strategies - GF Growth Navigation One-Year Holding A, managed by Wu Yuanyi, has benefited from a strategic increase in its Hong Kong stock allocation from approximately 5% to 32% over recent quarters, effectively capturing the Hong Kong market's upward trend [2]. - The fund has focused on new consumption and internet technology sectors, which have shown significant elasticity during the recent market rally [2]. - GF Growth Start One-Year Holding A, managed by Chen Yunzhong, has also increased its allocation to nearly full capacity, focusing on technology growth stocks and high-end manufacturing assets [2]. Group 3: Index Funds - GF CSI Hong Kong Innovative Medicine ETF, GF North Exchange 50 Component A, and GF CSI Hong Kong Innovative Medicine Link A have achieved returns of 126.53%, 121.72%, and 111.20% respectively, serving as low-cost investment tools for capturing the Hong Kong innovative medicine and North Exchange market trends [2]. Group 4: Overall Fund Performance - In addition to the six funds that doubled their returns, GF Fund has 37 other funds with returns exceeding 50% in the past year, with 25 of these funds reaching historical net asset value highs this year [3]. - The comprehensive product layout and diversified investment capabilities of GF Fund have contributed to strong returns for investors [3].

Group 1 - The report indicates an increase in active equity positions, with a preference for dividend strategies and cyclical theme funds [4][10][27] - As of the end of June 2025, there are 446 fund advisory combinations on the Tian Tian Fund APP, an increase of 5 from the previous month, with a notable dominance of equity-debt central combinations [10][11] - The performance of the equity-debt central combinations shows that the aggressive type outperformed similar FOF products over the past year, while balanced and conservative types underperformed [16][19] Group 2 - The report highlights that the active equity funds favored by advisory combinations include cyclical themes, dividend strategies, growth styles, value themes, and technology themes [41][46] - The QDII funds that received significant allocations include the Huaxia Hang Seng Technology ETF and the Southern Nasdaq 100 A [47][52] - The report notes that the most favored passive equity funds include those focused on low volatility dividend strategies and Hong Kong banking sectors [53][54] Group 3 - The report tracks the changes in fund positions, indicating that conservative combinations reduced mixed funds while increasing index funds, and aggressive combinations reduced passive equity funds while increasing active equity funds [34][40] - The report also details the top ten active equity funds favored by advisory combinations, with a focus on value style and cyclical themes [43][46] - The report provides insights into the performance of thematic and regional advisory combinations, noting that the medical and renewable energy sectors outperformed their benchmarks [25][27][31]

Core Viewpoint - The QDII funds have shown remarkable performance in the first half of 2025, with equity products achieving net value growth rates close to 90%, driven by strong rebounds in the Hong Kong stock market, particularly in sectors like innovative drugs, new consumption, and technology [1][2]. QDII Fund Performance - As of June 26, 2025, the average net value growth rate of 312 equity QDII funds was 12.5%, with top performers primarily in the innovative drug and biopharmaceutical sectors [3]. - The fund managed by Zhang Wei, Huatai-PB Hong Kong Advantage Selection A, led the market with a net value growth rate of 89.15% [3]. - Other notable funds include Huatai-PB Hang Seng Innovative Drug ETF and GF CSI Hong Kong Innovative Drug ETF, both exceeding 54% growth [3]. Market Drivers - The strong performance of QDII funds is attributed to the robust performance of the Chinese market, particularly the significant rise in stock prices of Hong Kong internet technology companies [3]. - The Chinese macroeconomic landscape has shown signs of stabilization, with no significant negative impacts from tariff policies, and a trend of upward reversal in the fundamentals of the technology sector [3][4]. Investment Opportunities - Looking ahead to the second half of 2025, there are significant investment opportunities in Hong Kong stocks, especially in leading companies within the internet, innovative drugs, and new consumption sectors [5][6]. - The Hong Kong stock market is seen as being in a value recovery phase, with many high-quality companies successfully expanding globally, which has not yet been fully priced in [6]. Sector Focus - The technology sector in Hong Kong is highlighted as a key area for investment, driven by the macroeconomic narrative of asset revaluation and the rise of the Chinese technology industry [7]. - The Hang Seng Technology Index is characterized by low valuations and high growth potential, with expectations of strong earnings growth for its constituent companies [8]. Global Market Insights - There is a positive outlook for the US stock market, particularly in the technology sector, supported by a clearer shift in monetary policy and favorable fiscal signals [8][9]. - Key factors for the US market include anticipated interest rate cuts, easing financial regulations, and a manageable risk environment in the bond market [8][9]. Regional Opportunities - Investment managers are focusing on three main areas for the second half: the US technology sector, gold as a hedge against geopolitical changes and a weakening dollar, and regional opportunities in East and Southeast Asia [9].

Quantitative Models and Construction 1. Model Name: Hang Seng Hong Kong Innovative Drug Index (CNY) - **Model Construction Idea**: The index selects up to 50 listed companies in the Hong Kong market whose main business involves innovative drug research and development, reflecting the overall performance of innovative drug-themed listed companies in Hong Kong[37][61] - **Model Construction Process**: - **Sample Space**: Combines the sample space of the CSI Hong Kong 300 Index and the CSI Hong Kong Stock Connect Composite Index[38] - **Selection Criteria**: - Liquidity: Average daily turnover over the past year must not be less than HKD 10 million - Business Focus: Companies involved in innovative drug R&D or providing related services are selected - Market Cap: Top 50 securities by average daily market cap over the past year are included, or all securities if fewer than 50 meet the criteria - **Weighting Method**: Free-float market capitalization weighting, with individual stock weights capped at 10%[38] - **Adjustment Frequency**: Semi-annual adjustments in June and December[38] - **Model Evaluation**: The index focuses on mid-to-large innovative drug enterprises, with a high degree of industry purity, as 100% of its constituents belong to the "Pharmaceuticals and Biotechnology" secondary industry[43][44] --- Model Backtesting Results 1. Hang Seng Hong Kong Innovative Drug Index - **Annualized Return**: 8.54% (2019.1.1 - 2025.5.31)[49][50] - **Annualized Sharpe Ratio (IR)**: 0.41[49][50] - **Annualized Volatility**: 35.93%[49][50] - **Maximum Drawdown**: -68.18%[49][50]